1. Home
  2. RZLT vs SGHT Comparison

RZLT vs SGHT Comparison

Compare RZLT & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rezolute Inc. (NV)

RZLT

Rezolute Inc. (NV)

HOLD

Current Price

$2.17

Market Cap

187.3M

Sector

Health Care

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$7.47

Market Cap

395.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RZLT
SGHT
Founded
2010
2011
Country
United States
United States
Employees
N/A
216
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.3M
395.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RZLT
SGHT
Price
$2.17
$7.47
Analyst Decision
Strong Buy
Buy
Analyst Count
6
8
Target Price
$12.33
$7.66
AVG Volume (30 Days)
15.2M
298.2K
Earning Date
02-11-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,052,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$12.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$2.03
52 Week High
$11.46
$9.24

Technical Indicators

Market Signals
Indicator
RZLT
SGHT
Relative Strength Index (RSI) 30.49 42.97
Support Level $2.16 $7.70
Resistance Level $2.82 $9.24
Average True Range (ATR) 0.33 0.60
MACD 0.07 -0.18
Stochastic Oscillator 52.19 9.71

Price Performance

Historical Comparison
RZLT
SGHT

About RZLT Rezolute Inc. (NV)

Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

Share on Social Networks: